Clinical study of Huatuo Zaizao pills on nervous dysfunction after cerebral microvascular disease

Beijing Friendship Hospital, Capital Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•Inclusion criteria for cerebral microvascular disease:
•(1) Conforming to the imaging diagnosis of cerebral microvascular disease, including lacunar cerebral infarction (LI), leukoencephalopathy (WML) and cerebral microhemorrhage (CMB).
•(2) For mild cognitive impairment, refer to rock-Wood diagnostic criteria for vascular cognitive impairment or the diagnostic criteria for vascular dementia jointly established by the National Institute of Neurological Diseases and Stroke and the International Society for Neuroscience Research and Education (NINDS-AIREN).
•(3) Ages 40-80 years old.
•(4) No heart, liver and kidney dysfunction.
•(5) Those who have signed informed consent forms with the patients and their family members,and have been examined and approved by the medical Ethics Committee of the hospital;
•Cognitive impairment (MCI) group: combined with mild cognitive impairment on the basis of the above criteria.
•Vascular Parkinson's disease (PD) group:combined with extrapyramidal symptoms on the basis of the above criteria,which is considered to be related to cerebral microvascular disease.

•(1) Previous history of chronic pain;
•(2) Patients with cerebral hemorrhage or hemorrhagic cerebral infarction;
•(3) Patients with various types of dementia;
•(4) Pregnant or lactating women;
•(5) Having a history of drug allergy or multiple food allergies;
•(6) Patients with concurrent primary diseases such as endocrine system and severe heart, liver, kidney and hematopoietic system.
•(7) Combined psychiatric or mood disorders (Hamilton anxiety > 9, Depression > 13).
•(8) Participate in other drug clinical trials at the same time.

发起方